Medical professional network Doximity (NYSE: DOCS) met Wall Street’s revenue expectations in Q1 CY2026, with sales up 5.1% year on year to $145.4 million. On the other hand, next quarter’s revenue guidance of $151.5 million was less impressive, coming in 1.1% below analysts’ estimates. Its non-GAAP profit of $0.26 per share was 7.9% below analysts’ consensus estimates.

Is now the time to buy DOCS? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Doximity’s first quarter results were met with a sharply negative market reaction, as management pointed to a combination of elevated AI-related expenses and persistent caution among pharmaceutical customers. CEO Jeffrey Tangney cited rapid uptake of Doximity’s AI workflow tools by physicians and highlighted a notable increase in engagement, but acknowledged that macro uncertainty and shorter-term spending commitments from clients weighed on the business. Management also addressed the drag on profitability from higher AI compute costs, noting that investments in platform capabilities and brand marketing led to a significant margin contraction.

Looking ahead, Doximity’s guidance reflects muted revenue growth, with management emphasizing the need for continued investment in AI solutions and a measured approach to monetization. CFO Matt Sonefeldt stated that the company expects near-term margins to remain pressured by increased R&D and marketing spend, while Perry Gold, Vice President of Investor Relations, highlighted ongoing uncertainty in the digital pharma ad market. Management framed 2026 as an "AI investment year,” balancing product development with prudent cost management as they seek to position Doximity for future growth in a constrained environment.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to surging AI engagement among doctors and a competitive but cautious pharma advertising environment, while highlighting recent leadership changes and the launch of commercial AI products.

• AI engagement surge: Doximity reported that nearly half of all U.S. doctors at hospital clients now use its workflow or scheduling tools, with over 800,000 unique quarterly active prescribers—up 30% year-over-year. CEO Jeffrey Tangney noted, “Doctors increasingly turn to us to be their AI assistant,” and nearly half of these prescribers used Doximity’s AI tools last quarter.
• Commercial AI product launch: The company launched its AI Search suite for pharmaceutical clients, designed to help pharma brands reach prescribers during clinical research moments. Early deals have been signed with top 20 pharma manufacturers, but management cautioned that regulatory reviews and a nascent market will delay meaningful revenue contribution until later this year.
• Rising AI compute costs: Non-GAAP gross margin declined primarily due to increased AI compute expenses, reflecting a steep ramp in AI tool usage that outpaced overall workflow engagement. Management indicated that higher R&D and compute investment will continue to weigh on margins in the near term.
• Leadership changes: Doximity appointed Matt Sonefeldt as CFO, bringing experience from LinkedIn, Atlassian, and DocuSign, and named Dr. Steve Zatz, a veteran of WebMD Medscape, as President. Management believes these hires will strengthen the company’s platform and client engagement expertise.
• Pharma ad market uncertainty: Short-term demand in the digital pharma ad market remained soft, with clients favoring innovation-focused or low-cost options. Perry Gold explained that policy uncertainty and macro risk were driving shorter planning horizons and limited budget visibility, creating a challenging backdrop for growth.

Drivers of Future Performance

Doximity’s outlook is shaped by ongoing investment in AI, uncertain pharma ad demand, and the need to balance innovation with operational discipline.

• AI monetization ramp: Management expects limited revenue impact from AI Search in the first half of the year, citing regulatory review cycles and early-stage client adoption. However, they believe that success in this area could unlock a new, multi-billion-dollar market over time, expanding Doximity’s addressable opportunity beyond traditional pharma advertising.
• Margin pressure from investment: The company projects continued elevated R&D, compute, and brand marketing expenses, which are expected to keep non-GAAP operating margins in the high-40% range. CFO Matt Sonefeldt said the focus is on "long-term platform potential" rather than immediate margin expansion, and noted that higher stock-based compensation will be offset by share repurchases.
• External headwinds persist: Doximity anticipates digital pharma ad market growth to remain modest, at or below 5%, due to policy and macroeconomic uncertainty. Management does not expect a major shift in client budgets until broader industry and regulatory conditions improve, and they are not planning to compete on price with low-cost ad offerings.

Catalysts in Upcoming Quarters

Looking ahead, our analysts will watch (1) the rate of adoption and monetization for Doximity’s commercial AI Search suite among pharma clients, (2) the pace of margin recovery as AI-related costs normalize and free cash flow trends stabilize, and (3) signs of renewed budget commitment from pharmaceutical clients as macro and policy visibility improve. Execution on these fronts will determine whether Doximity’s AI investments can translate into sustainable growth.

Doximity currently trades at $18.51, down from $23.83 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.